OTCMKTS:BRTXQ

BioRestorative Therapies Competitors

$0.03
+0.01 (+123.14 %)
(As of 11/18/2020)
Add
Compare
Today's Range
$0.01
Now: $0.03
$0.03
50-Day Range
$0.01
MA: $0.01
$0.03
52-Week Range
$0.00
Now: $0.03
$0.06
Volume295.59 million shs
Average Volume62.17 million shs
Market Capitalization$44.27 million
P/E RatioN/A
Dividend YieldN/A
Beta102.36

Competitors

BioRestorative Therapies (OTCMKTS:BRTXQ) Vs. FMS, DVA, SHC, PGNY, TVTY, and OTRK

Should you be buying BRTXQ stock or one of its competitors? Companies in the industry of "miscellaneous health & allied services, not elsewhere classified" are considered alternatives and competitors to BioRestorative Therapies, including Fresenius Medical Care AG & Co. KGaA (FMS), DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Tivity Health (TVTY), and Ontrak (OTRK).

BioRestorative Therapies (OTCMKTS:BRTXQ) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, earnings, analyst recommendations, institutional ownership, profitability and risk.

Insider and Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. 12.2% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares BioRestorative Therapies and Fresenius Medical Care AG & Co. KGaA's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioRestorative Therapies$110,000.00402.45$-12,520,000.00N/AN/A
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.14$1.34 billion$2.5315.07

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than BioRestorative Therapies.

Profitability

This table compares BioRestorative Therapies and Fresenius Medical Care AG & Co. KGaA's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioRestorative TherapiesN/AN/AN/A
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%

Risk & Volatility

BioRestorative Therapies has a beta of 102.36, suggesting that its stock price is 10,136% more volatile than the S&P 500. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for BioRestorative Therapies and Fresenius Medical Care AG & Co. KGaA, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioRestorative Therapies0000N/A
Fresenius Medical Care AG & Co. KGaA19702.35

Fresenius Medical Care AG & Co. KGaA has a consensus price target of $45.00, suggesting a potential upside of 18.02%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than BioRestorative Therapies.

Summary

Fresenius Medical Care AG & Co. KGaA beats BioRestorative Therapies on 9 of the 12 factors compared between the two stocks.

DaVita (NYSE:DVA) and BioRestorative Therapies (OTCMKTS:BRTXQ) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.

Analyst Ratings

This is a summary of recent recommendations and price targets for DaVita and BioRestorative Therapies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita13102.00
BioRestorative Therapies0000N/A

DaVita presently has a consensus target price of $114.60, suggesting a potential upside of 1.32%. Given DaVita's higher probable upside, equities analysts clearly believe DaVita is more favorable than BioRestorative Therapies.

Risk & Volatility

DaVita has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 102.36, meaning that its stock price is 10,136% more volatile than the S&P 500.

Profitability

This table compares DaVita and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
BioRestorative TherapiesN/AN/AN/A

Valuation and Earnings

This table compares DaVita and BioRestorative Therapies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion1.09$810.98 million$5.4020.95
BioRestorative Therapies$110,000.00402.45$-12,520,000.00N/AN/A

DaVita has higher revenue and earnings than BioRestorative Therapies.

Insider and Institutional Ownership

91.7% of DaVita shares are held by institutional investors. 1.0% of DaVita shares are held by company insiders. Comparatively, 12.2% of BioRestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

DaVita beats BioRestorative Therapies on 9 of the 12 factors compared between the two stocks.

BioRestorative Therapies (OTCMKTS:BRTXQ) and Sotera Health (NYSE:SHC) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Profitability

This table compares BioRestorative Therapies and Sotera Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioRestorative TherapiesN/AN/AN/A
Sotera HealthN/AN/AN/A

Earnings & Valuation

This table compares BioRestorative Therapies and Sotera Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioRestorative Therapies$110,000.00402.45$-12,520,000.00N/AN/A
Sotera HealthN/AN/AN/AN/AN/A

Sotera Health has lower revenue, but higher earnings than BioRestorative Therapies.

Analyst Ratings

This is a breakdown of current recommendations and price targets for BioRestorative Therapies and Sotera Health, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioRestorative Therapies0000N/A
Sotera Health001003.00

Sotera Health has a consensus target price of $32.75, indicating a potential upside of 24.57%. Given Sotera Health's higher possible upside, analysts plainly believe Sotera Health is more favorable than BioRestorative Therapies.

Summary

Sotera Health beats BioRestorative Therapies on 2 of the 3 factors compared between the two stocks.

Progyny (NASDAQ:PGNY) and BioRestorative Therapies (OTCMKTS:BRTXQ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Progyny and BioRestorative Therapies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Progyny00603.00
BioRestorative Therapies0000N/A

Progyny presently has a consensus target price of $38.8333, suggesting a potential downside of 26.69%. Given Progyny's higher possible upside, research analysts clearly believe Progyny is more favorable than BioRestorative Therapies.

Valuation and Earnings

This table compares Progyny and BioRestorative Therapies' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Progyny$229.68 million20.11$-8,570,000.00$0.11481.55
BioRestorative Therapies$110,000.00402.45$-12,520,000.00N/AN/A

Progyny has higher revenue and earnings than BioRestorative Therapies.

Insider & Institutional Ownership

58.5% of Progyny shares are owned by institutional investors. 33.3% of Progyny shares are owned by company insiders. Comparatively, 12.2% of BioRestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Progyny has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 102.36, suggesting that its share price is 10,136% more volatile than the S&P 500.

Profitability

This table compares Progyny and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Progyny1.03%7.43%5.04%
BioRestorative TherapiesN/AN/AN/A

Summary

Progyny beats BioRestorative Therapies on 10 of the 12 factors compared between the two stocks.

Tivity Health (NASDAQ:TVTY) and BioRestorative Therapies (OTCMKTS:BRTXQ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Volatility and Risk

Tivity Health has a beta of 2.49, indicating that its share price is 149% more volatile than the S&P 500. Comparatively, BioRestorative Therapies has a beta of 102.36, indicating that its share price is 10,136% more volatile than the S&P 500.

Institutional and Insider Ownership

91.6% of Tivity Health shares are owned by institutional investors. 11.8% of Tivity Health shares are owned by insiders. Comparatively, 12.2% of BioRestorative Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Tivity Health and BioRestorative Therapies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tivity Health-47.44%128.43%6.11%
BioRestorative TherapiesN/AN/AN/A

Earnings and Valuation

This table compares Tivity Health and BioRestorative Therapies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tivity Health$1.13 billion1.03$-286,820,000.00$2.0211.68
BioRestorative Therapies$110,000.00402.45$-12,520,000.00N/AN/A

BioRestorative Therapies has lower revenue, but higher earnings than Tivity Health.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Tivity Health and BioRestorative Therapies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tivity Health12502.50
BioRestorative Therapies0000N/A

Tivity Health presently has a consensus target price of $22.1250, indicating a potential downside of 6.25%. Given Tivity Health's higher probable upside, research analysts clearly believe Tivity Health is more favorable than BioRestorative Therapies.

BioRestorative Therapies (OTCMKTS:BRTXQ) and Ontrak (NASDAQ:OTRK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends.

Institutional and Insider Ownership

27.5% of Ontrak shares are owned by institutional investors. 12.2% of BioRestorative Therapies shares are owned by insiders. Comparatively, 58.2% of Ontrak shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares BioRestorative Therapies and Ontrak's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioRestorative TherapiesN/AN/AN/A
Ontrak-43.10%N/A-58.54%

Risk and Volatility

BioRestorative Therapies has a beta of 102.36, meaning that its stock price is 10,136% more volatile than the S&P 500. Comparatively, Ontrak has a beta of 2.52, meaning that its stock price is 152% more volatile than the S&P 500.

Earnings and Valuation

This table compares BioRestorative Therapies and Ontrak's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioRestorative Therapies$110,000.00402.45$-12,520,000.00N/AN/A
Ontrak$35.10 million16.02$-25,660,000.00($1.15)-27.63

BioRestorative Therapies has higher earnings, but lower revenue than Ontrak.

Analyst Ratings

This is a breakdown of current recommendations for BioRestorative Therapies and Ontrak, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioRestorative Therapies0000N/A
Ontrak02302.60

Ontrak has a consensus target price of $47.20, indicating a potential upside of 48.52%. Given Ontrak's higher probable upside, analysts clearly believe Ontrak is more favorable than BioRestorative Therapies.

Summary

BioRestorative Therapies beats Ontrak on 6 of the 11 factors compared between the two stocks.


BioRestorative Therapies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.7$38.13+0.6%$22.33 billion$19.58 billion15.13
DaVita logo
DVA
DaVita
1.7$113.11+2.9%$12.37 billion$11.39 billion16.96High Trading Volume
Sotera Health logo
SHC
Sotera Health
1.8$26.29+1.8%$7.44 billionN/A0.00
Progyny logo
PGNY
Progyny
1.5$52.97+5.0%$4.62 billion$229.68 million481.55Insider Selling
Gap Down
Tivity Health logo
TVTY
Tivity Health
1.0$23.60+0.0%$1.16 billion$1.13 billion-2.13
Ontrak logo
OTRK
Ontrak
1.7$31.78+1.4%$562.19 million$35.10 million-18.69
SOC Telemed logo
TLMD
SOC Telemed
1.6$6.65+4.5%$510.54 millionN/A0.00
Viemed Healthcare logo
VMD
Viemed Healthcare
1.1$9.70+0.9%$380.09 million$80.26 million13.47
HemaCare logo
HEMA
HemaCare
0.5$25.31+0.6%$346.52 millionN/A0.00
Caladrius Biosciences logo
CLBS
Caladrius Biosciences
1.5$1.53+1.3%$91.03 millionN/A-2.39Decrease in Short Interest
News Coverage
Baudax Bio logo
BXRX
Baudax Bio
1.4$1.07+0.9%$75.05 millionN/A-0.31Increase in Short Interest
Cryo-Cell International logo
CCEL
Cryo-Cell International
0.9$9.88+2.1%$74.80 million$31.80 million24.70High Trading Volume
Gap Down
GRNV
GreenVision Acquisition
0.3$10.18+0.1%$73.17 millionN/A0.00Increase in Short Interest
Emmaus Life Sciences logo
EMMA
Emmaus Life Sciences
0.2$1.30+0.0%$63.68 million$1.32 million0.00
PFHOD
Pacific Health Care Organization
0.5$1.25+228.0%$52.48 million$6.80 million0.00Gap Up
CTYX
Curative Biotechnology
0.0$0.12+19.3%$47.20 millionN/A0.00
BioRestorative Therapies logo
BRTX
BioRestorative Therapies
0.6$0.01+3.0%$16.56 million$110,000.000.00Gap Down
PFHO
Pacific Health Care Organization
0.8$1.12+3.1%$14.27 million$7.33 million0.00Gap Up
GNOW
American Caresource
0.7$0.01+0.0%$124,000.00N/A0.00Gap Down
HYBE
Hybrid Energy
0.0$0.00+0.0%$0.00N/A0.00
QMED
QMed
0.2$0.00+10.0%$0.00N/A0.00Gap Up
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.